Skip to main content
. 2018 Sep 6;3(17):e120750. doi: 10.1172/jci.insight.120750

Figure 3. The combination of IL-22 and cyclosporine A produced larger, more proliferative tumors in a murine xenograft model.

Figure 3

(A) Following engraftment with A431 squamous cell carcinoma (SCC) cells, nude mice were randomized to 4 treatment groups at day 7: vehicle (n = 9), IL-22 (4 μg/d i.p. M–F, n = 9), cyclosporine A (CSA) (20 mg/kg i.p., n = 8), or both IL-22 and CSA (n = 6). The difference in tumor volume at day 11 is shown. (B) Difference in tumor growth at day 18. (C) Representative tumors at endpoint, day 27. Scale bar: 1 cm. (D) Immunohistochemistry (shown at original magnification, ×10) and quantification of positively stained cells for proliferative cell nuclear antigen (PCNA) performed on paraffin-embedded tumors harvested at endpoint. Data represent mean of 5 experiments ± SEM. *P < 0.05, ****P < 0.0001, determined by 1-way ANOVA with Dunnett’s multiple comparisons test.